C—Side by side
Compare
Up to four peptides. Opinion rows are labeled. Copy the URL to share.
| Field | CJC-1295 | Ipamorelin |
|---|---|---|
| Type | Research Only | Research Only |
| Regulatory status | Not FDA-approved; no verified marketing authorization | Not FDA-approved; no verified marketing authorization |
| Compounding status | Not cleared (advisory panel rejected) | Not cleared (advisory panel rejected) |
| FDA-approved indications | None | None |
| Categories | Growth hormone axis | Growth hormone axis |
| Claimed uses |
|
|
| Mechanism | Long-acting growth-hormone-releasing hormone analogue; the DAC form binds albumin to prolong exposure and raise GH and IGF-1. Products called non-DAC CJC-1295 are not equivalent to the studied long-acting form. | Ghrelin-receptor agonist that stimulates growth-hormone release and can affect gastrointestinal motility. Hormone release alone does not establish anti-aging benefit. |
| Evidence level | Small/early human studies | Small/early human studies |
| Evidence / Hype (opinion) | Evidence Hype | Evidence Hype |
| Momentum (opinion) | Watch | Watch |
| Routes | — | — |
| WADA | Prohibited | Prohibited |
| Where it stands (opinion) | The December 2024 FDA advisory committee opposed listing CJC-1295-related substances for compounding. WADA 2026 S2.2.4 prohibits CJC-1295. | Historical phase 2 research does not establish wellness efficacy. Its 503A nomination was withdrawn; acetate remains Category 2 under 503B, and WADA 2026 S2.2.4 prohibits it. |
| Last reviewed | 2026-10-30 | 2026-10-30 |
| News (30d) | 0 | 0 |